PMC:7600245 / 41455-42003 4 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T311 | 0-115 | Sentence | denotes | Currently, selinexor is being evaluated in at least two phase 2 randomized trials in the U.S. in COVID-19 patients. |
| T312 | 116-548 | Sentence | denotes | One is to evaluate the activity, safety and reduction in mortality of two regimens of low-dose selinexor in patients with moderate or severe COVID-19 (NCT04355676, n = 80) and the other is to evaluate the activity of low-dose selinexor and its effect on the clinical recovery, viral load, length of hospitalization, and rate of morbidity and mortality in participants with severe COVID-19 compared to placebo (NCT04349098, n = 230). |